Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Sale
Global Pseudobulbar Affect Treatment Market Share, Size, Trends, Growth, Forecast: By Treatment: Medication, Occupational Therapy, Others; By Route of Administration: Oral, Parenteral, Others; By Drug Class: Antidepressants, Nuedexta; By Distribution Channels: Retail Pharmacies, Others; Regional Analysis; Competitive Landscape; 2023-2028
Global Pseudobulbar Affect Treatment Market Outlook
The global pseudobulbar affect treatment market is expected to grow at a CAGR of 9.20% during the forecast period of 2023-2028, driven by the rising prevalence of neurological disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Pseudobulbar Affect Treatment Market Trends
Pseudobulbar affect is a neurological disorder that causes sudden outbursts of laughter or crying that are uncontrollable. This condition can either develop through a brain injury or an underlying neurological condition, such as amyotrophic lateral sclerosis. Although there is no guaranteed cure available for the condition, there are medications available that can help in managing it.
- The rising prevalence of the pseudobulbar affect is expected to enhance the market size as it has propelled the demand for effective treatment solutions that can help with the symptoms of the disorder. Healthcare providers and centres are increasingly providing advanced and improved treatment methods to patients to meet the rising demand.
- The market for pseudobulbar affect treatment is expected to develop significantly owing to the increasing investments in healthcare infrastructure development. Multiple government organisations have increased their healthcare expenditure to improve the infrastructure and facilities.
- The rising number of initiatives taken by various organisations to develop innovative and improved treatment options can further propel awareness about treatment solutions. In addition, it will further enhance the demand for treatments in the market, which will augment the market value.
Global Pseudobulbar Affect Treatment Market Analysis
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on treatment, the market can be segmented into medication and occupational therapy, among others. Based on the route of administration, it can be bifurcated into oral and parental, among others. Based on drug class, the market divisions include antidepressants and nuedexta, among others. Based on distribution channels, the market can be segmented into retail pharmacies, hospital pharmacies, and online, among others. The regional markets for the pseudobulbar affect treatment market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global pseudobulbar effect treatment market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.
- Avanir Pharmaceuticals, Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Arrow Pharmaceuticals
- AbbVie Inc.
- Others
Treatment Types for Pseudobulbar Affect Treatment in the Market
The market for pseudobulbar affect treatment, based on product type, can be bifurcated into medication and occupational therapy, among others.
The medication segment is expected to hold a major share of the market owing to rising efforts and investments to develop new and improved medications. Although companies are trying to develop new treatment options, there is only one medication approved by the Food and Drug Administration known as Dextromethorphan hydrobromide and quinidine sulfate (Nuedexta), which is specifically developed for Pseudobulbar affect treatment (PBA).
Regional Outlook for the Pseudobulbar Affect Treatment Global Market
Based on regional markets, the market divisions include North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
North America is expected to dominate the pseudobulbar affect treatment market due to the rising prevalence of neurological disorders. The market development is aided by the growing geriatric population in the region. Furthermore, growing healthcare expenditures and the presence of significant key competitors will drive the market's growth rate in this region even faster.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Competitive Landscape
Avanir Pharmaceuticals, Inc., was founded in 1988 and the headquarter is located in California, United States. It is a pharmaceutical manufacturing company that operates in the field with an aim to deliver innovative medicines to patients with central nervous system disorders. The company is a subsidiary of Otsuka America, Inc. (OAI), which is a holding company established in the United States in 1989.
Pfizer Inc. is a pharmaceutical and biotechnology company, headquartered in New York City, United States. The company was established in 1849 and they were one of the leading figures engaged in the development of a vaccine for COVID-19. Since the beginning of its operations, the company has evolved their product portfolio to include multitudes of products like Comirnaty, Eliquis, Ibrance, Prevnar family, and Xeljanz.
Eli Lilly and Company. is a global pharmaceutical company, which was founded in 1876 and headquartered in Indianapolis, United States. The company’s speciality lies in pharmaceutical development, biotech, and biopharmaceuticals. They have expertise in disease areas, such as Alzheimer’s, cancer, diabetes, immunology, obesity, and pain.
Other market players include Arrow Pharmaceuticals and AbbVie Inc., among others.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2018-2022 |
| Forecast Period | 2023-2028 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by Drug Class |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Region
7 Opportunities and Challenges in the Market
8 Global Pseudobulbar Affect Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Pseudobulbar Affect Treatment Historical Market (2018-2022)
8.3 Global Pseudobulbar Affect Treatment Market Forecast (2023-2028)
8.4 Global Pseudobulbar Affect Treatment Market by Treatment
8.4.1 Medication
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2018-2022)
8.4.1.3 Forecast Trend (2023-2028)
8.4.2 Occupational Therapy
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2018-2022)
8.4.2.3 Forecast Trend (2023-2028)
8.4.3 Others
8.5 Global Pseudobulbar Affect Treatment Market by Route of Administration
8.5.1 Oral
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2018-2022)
8.5.1.3 Forecast Trend (2023-2028)
8.5.2 Parenteral
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2018-2022)
8.5.2.3 Forecast Trend (2023-2028)
8.5.3 Others
8.6 Global Pseudobulbar Affect Treatment Market by Drug Class
8.6.1 Antidepressants
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2018-2022)
8.6.1.3 Forecast Trend (2023-2028
8.6.2 Nuedexta
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2018-2022)
8.6.2.3 Forecast Trend (2023-2028)
8.7 Global Pseudobulbar Affect Treatment Market by Distribution Channels
8.7.1 Retail Pharmacies
8.7.1.1 Market Share
8.7.1.2 Historical Trend (2018-2022)
8.7.1.3 Forecast Trend (2023-2028)
8.7.2 Hospital Pharmacies
8.7.2.1 Market Share
8.7.2.2 Historical Trend (2018-2022)
8.7.2.3 Forecast Trend (2023-2028)
8.7.3 Online
8.7.3.1 Market Share
8.7.3.2 Historical Trend (2018-2022)
8.7.3.3 Forecast Trend (2023-2028)
8.7.4 Others
8.8 Global Pseudobulbar Affect Treatment Market by Region
8.8.1 North America
8.8.1.1 Market Share
8.8.1.2 Historical Trend (2018-2022)
8.8.1.3 Forecast Trend (2023-2028)
8.8.2 Europe
8.8.2.1 Market Share
8.8.2.2 Historical Trend (2018-2022)
8.8.2.3 Forecast Trend (2023-2028)
8.8.3 Asia Pacific
8.8.3.1 Market Share
8.8.3.2 Historical Trend (2018-2022)
8.8.3.3 Forecast Trend (2023-2028)
8.8.4 Latin America
8.8.4.1 Market Share
8.8.4.2 Historical Trend (2018-2022)
8.8.4.3 Forecast Trend (2023-2028)
8.8.5 Middle East and Africa
8.8.5.1 Market Share
8.8.5.2 Historical Trend (2018-2022)
8.8.5.3 Forecast Trend (2023-2028)
9 North America Pseudobulbar Affect Treatment Market Analysis
9.1 United States of America
9.1.1 Market Share
9.1.2 Historical Trend (2018-2022)
9.1.3 Forecast Trend (2023-2028)
9.2 Canada
9.2.1 Market Share
9.2.2 Historical Trend (2018-2022)
9.2.3 Forecast Trend (2023-2028)
10 Europe Pseudobulbar Affect Treatment Market Analysis
10.1 United Kingdom
10.1.1 Market Share
10.1.2 Historical Trend (2018-2022)
10.1.3 Forecast Trend (2023-2028)
10.2 Germany
10.2.1 Market Share
10.2.2 Historical Trend (2018-2022)
10.2.3 Forecast Trend (2023-2028)
10.3 France
10.3.1 Market Share
10.3.2 Historical Trend (2018-2022)
10.3.3 Forecast Trend (2023-2028)
10.4 Italy
10.4.1 Market Share
10.4.2 Historical Trend (2018-2022)
10.4.3 Forecast Trend (2023-2028)
10.5 Others
11 Asia Pacific Pseudobulbar Affect Treatment Market Analysis
11.1 China
11.1.1 Market Share
11.1.2 Historical Trend (2018-2022)
11.1.3 Forecast Trend (2023-2028)
11.2 Japan
11.2.1 Market Share
11.2.2 Historical Trend (2018-2022)
11.2.3 Forecast Trend (2023-2028)
11.3 India
11.3.1 Market Share
11.3.2 Historical Trend (2018-2022)
11.3.3 Forecast Trend (2023-2028)
11.4 ASEAN
11.4.1 Market Share
11.4.2 Historical Trend (2018-2022)
11.4.3 Forecast Trend (2023-2028)
11.5 Australia
11.5.1 Market Share
11.5.2 Historical Trend (2018-2022)
11.5.3 Forecast Trend (2023-2028)
11.6 Others
12 Latin America Pseudobulbar Affect Treatment Market Analysis
12.1 Brazil
12.1.1 Market Share
12.1.2 Historical Trend (2018-2022)
12.1.3 Forecast Trend (2023-2028)
12.2 Argentina
12.2.1 Market Share
12.2.2 Historical Trend (2018-2022)
12.2.3 Forecast Trend (2023-2028)
12.3 Mexico
12.3.1 Market Share
12.3.2 Historical Trend (2018-2022)
12.3.3 Forecast Trend (2023-2028)
12.4 Others
13 Market Dynamics
13.1 SWOT Analysis
13.1.1 Strengths
13.1.2 Weaknesses
13.1.3 Opportunities
13.1.4 Threats
13.2 Porter’s Five Forces Analysis
13.2.1 Supplier’s Power
13.2.2 Buyer’s Power
13.2.3 Threat of New Entrants
13.2.4 Degree of Rivalry
13.2.5 Threat of Substitutes
14 Competitive Landscape
14.1 Market Structure
14.2 Company Profiles
14.2.1 Avanir Pharmaceuticals, Inc.
14.2.1.1 Company Overview
14.2.1.2 Product Portfolio
14.2.1.3 Demographic Reach and Achievements
14.2.1.4 Certifications
14.2.2 Pfizer Inc.
14.2.2.1 Company Overview
14.2.2.2 Product Portfolio
14.2.2.3 Demographic Reach and Achievements
14.2.2.4 Certifications
14.2.3 Eli Lilly and Company
14.2.3.1 Company Overview
14.2.3.2 Product Portfolio
14.2.3.3 Demographic Reach and Achievements
14.2.3.4 Certifications
14.2.4 Arrow Pharmaceuticals
14.2.4.1 Company Overview
14.2.4.2 Product Portfolio
14.2.4.3 Demographic Reach and Achievements
14.2.4.4 Certifications
14.2.5 AbbVie Inc.
14.2.5.1 Company Overview
14.2.5.2 Product Portfolio
14.2.5.3 Demographic Reach and Achievements
14.2.5.4 Certifications
14.2.6 Others
15 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Pseudobulbar Affect Treatment Market: Key Industry Highlights, 2018 and 2028
2. Global Pseudobulbar Affect Treatment Historical Market: Breakup by Treatment (USD Million), 2018-2022
3. Global Pseudobulbar Affect Treatment Market Forecast: Breakup by Treatment (USD Million), 2023-2028
4. Global Pseudobulbar Affect Treatment Historical Market: Breakup by Route of Administration (USD Million), 2018-2022
5. Global Pseudobulbar Affect Treatment Market Forecast: Breakup by Route of Administration (USD Million), 2023-2028
6. Global Pseudobulbar Affect Treatment Historical Market: Breakup by Drug Class (USD Million), 2018-2022
7. Global Pseudobulbar Affect Treatment Market Forecast: Breakup by Drug Class (USD Million), 2023-2028
8. Global Pseudobulbar Affect Treatment Historical Market: Breakup by Distribution Channels (USD Million), 2018-2022
9. Global Pseudobulbar Affect Treatment Market Forecast: Breakup by Distribution Channels (USD Million), 2023-2028
10. Global Pseudobulbar Affect Treatment Historical Market: Breakup by Region (USD Million), 2018-2022
11. Global Pseudobulbar Affect Treatment Market Forecast: Breakup by Region (USD Million), 2023-2028
12. North America Pseudobulbar Affect Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
13. North America Pseudobulbar Affect Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
14. Europe Pseudobulbar Affect Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
15. Europe Pseudobulbar Affect Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
16. Asia Pacific Pseudobulbar Affect Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
17. Asia Pacific Pseudobulbar Affect Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
18. Latin America Pseudobulbar Affect Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
19. Latin America Pseudobulbar Affect Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
20. Middle East and Africa Pseudobulbar Affect Treatment Historical Market: Breakup by Country (USD Million), 2018-2022
21. Middle East and Africa Pseudobulbar Affect Treatment Market Forecast: Breakup by Country (USD Million), 2023-2028
22. Global Pseudobulbar Affect Treatment Market Structure.
Key Questions Answered in the Report
The market is expected to grow at a CAGR of 9.20% during the forecast period of 2023-2028.
The market growth is driven by the growing prevalence of neurological diseases and increasing investment in research and development to develop an improved and effective treatment solution.
The multiple plans implemented by governments around the world to develop the healthcare infrastructure can be a major boon to the market.
The regional markets for pseudobulbar affect treatment include North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa.
The treatments available in the market include medication and occupational therapy, among others.
The different routes of application for treatment include oral and parental, among others.
The drug classes available in the market include antidepressants and nuedexta, among others.
The primary distribution channels for pseudobulbar affect treatments include retail pharmacies, hospital pharmacies, and online, among others.
The key players in the market include Avanir Pharmaceuticals, Inc., Pfizer Inc., Eli Lilly and Company, Arrow Pharmaceuticals, and AbbVie Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 2199
$1799
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$3199$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$4199$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$5199$4999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
NEWSLETTER